Key facts
- OVA’s last known valuation is $4.4M (Apr 2025).
- It has raised $720K; the latest was Seed Round ($720K) in Apr 2025.
- Notable investors include SyndicateRoom, Ventures Together, Efstratios Chatzigiannis, Era VC, Gemma Bellman — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for OVA
- ·The full record, as it builds
Funding rounds
No funding rounds for OVA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OVA
Manufacturer of reproductive health supplements intended to support fertility, hormonal balance, and overall reproductive wellness. The company offers clinically-backed formulations developed by fertility specialists, including targeted products for egg and sperm health, hormonal regulation, and pregnancy support, therapeutic dosages, enabling individuals and couples navigating conception, IVF, and science-driven nutritional support tailored to each stage of the reproductive journey.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Egham, United Kingdom
- Founded
- 2021
- Employees
- 6
- Website
- theovaco.com/
- Ownership
- Privately Held (backing)
OVA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OVA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OVA in its N-PORT filings yet. We sweep new filings monthly.